TCT-167 Drug Eluting Balloons Versus Balloon Angioplasty in Femoropopliteal and Infrapopliteal Vascular Disease Interventions: A Meta-analysis of Randomized Controlled Studies  by Kanmanthareddy, Arun K. et al.
Trends in baseline characteristics and outcomes of Medicare beneﬁciaries who underwent PCI from
1/2000-11/2012
Overall 2000 2002 2004 2006 2008 2010 2012
number 3387976 246528 293391 332988 318622 243418 204409 161667
median age(years) 75 75 75 75 75 75 75 75
female (%) 42.1 43.5 43.1 42.5 41.8 41.5 41 40.4
white (%) 90 91.5 90.9 90.4 89.9 89.5 88.6 88.1
HTN (%) 65.6 58.4 61.7 63.5 62.2 65.2 74.3 80.1
DM (%) 29.9 26 27.3 28.2 28.1 29 35.5 40.2
PVD (%) 4.9 4.3 4.7 4.5 4.7 4.7 5.2 6.6
Stroke/TIA (%) 4.2 4.4 4.2 3.9 3.7 4 4.7 5.6
HF (%) 23.4 22.3 22.3 22.4 22.6 21.3 26.2 29.9
renal failure (%) 10 3.6 4.5 5.4 12.2 10.5 17.6 24.5
acute MI (%) 29.9 26.9 27.5 26.1 25.9 30.8 37.6 45.8
elective (%) 43.1 39.1 41.5 45.3 47.4 40.1 40.2 47
post-procedure LOS
(days)
2 2 2 2 2 2 2 3
hospital mortality (%) 2.1 2.1 2 1.8 1.8 2.1 2.4 3.1
30 day mortality (%) 3.1 3 2.8 2.6 2.7 3.2 3.7 4.6
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terized by higher comorbidity burden and higher incidence of acute
MI. Hospital mortality increased signiﬁcantly over time, especially
for patients presenting electively. Following adjustment for wors-
ening baseline characteristics over time, adjusted hospital mortality
was 42% higher in 2012 compared to 2000, OR 1.42 (95% CI 1.36–
1.48).
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BACKGROUND We aimed to evaluate the angiographic and long-term
clinical outcomes after treatment for left main coronary artery disease
(LMCAD) with bare-metal stents (BMS), ﬁrst-generation, and second-
generation drug-eluting stents (G1-DES and G2-DES).
METHODS The Left Main Coronary Stenting Registry in Japan is a
multicenter registry enrolling 1800 consecutive patients with
LMCAD treated with stent implantation between 2004 and 2012: 355
patients with BMS, 875 with G1-DES, and 570 with G2-DES. The
clinical endpoints assessed included all-cause death, cardiac death,
sudden death, deﬁnite or probable stent thrombosis, and target-
lesion revascularization (TLR). We distinguished in-hospital death
from long-term clinical outcomes. The 6-year cumulative rates of
adverse events were estimated by Kaplan-Meier methods with p
values from log-rank tests. The angiographic endpoint was deﬁned
as in-stent restenosis within one year after procedure. In addition
to restenosis at stent-implanted site, restenosis at bifurcation
site was deﬁned as a percent diameter >50% within 5 mm from
the stent-implanted bifurcation lesion in both main and side
branches.
RESULTS The median follow-up duration was 3.9 years (the ﬁrst
and third quarters, 2.2 and 5.9 years). Among patients with BMS,
G1-DES, and G2-DES, there were no signiﬁcant differences in the
cumulative 6-year incidences of all-cause death (24.8% vs. 23.0%
vs. 23.8%, p¼0.48), cardiac death (8.3% vs. 10.2% vs. 5.4%,
p¼0.65), sudden death (2.4% vs. 3.7% vs. 2.0%, p¼0.95), and deﬁ-
nite or probable stent thrombosis (1.6% vs. 0.8% vs. 2.1%, p¼0.11),whereas patients with BMS had a signiﬁcantly higher cumulative
rate of TLR than those with G1- and G2-DES (26.6% vs. 15.4% vs.
10.4%, p<0.001). In this study sample, 1394 patients (77.4%) un-
derwent follow-up angiography within one year after the initial
procedure. The in-stent restenosis rate was signiﬁcantly higher in
patients with BMS than in those with 1st and 2nd DES (27.2% vs.
11.7% vs. 5.7%, p<0.001). The restenosis rate in the proximal left
main stem showed no signiﬁcant difference between patients with
G1- and G2-DES (3.2% vs. 2.4%, p¼0.48), whereas the main and side
bifurcation restenosis rates were signiﬁcantly higher in patients
with G1-DES than in those with G2-DES (5.0% vs. 2.4%, p¼0.04 and
5.3% vs. 1.3%, p<0.001).
CONCLUSIONS DES for LMCAD appeared to be associated with more
favorable outcomes of TLR than BMS. Although G2-DES improved the
in-stent restenosis rate compared with G1-DES, especially in both
main and side bifurcation lesions, long-term clinical outcomes after
stent implantation for LMCAD were comparable between G1- and G2-
DES.
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BACKGROUND Peripheral vascular interventions with drug eluting
balloons (DEB) have been demonstrated to be superior to balloon
angioplasty (BA) in short-term follow up (6 months). Long-term out-
comes remain uncertain and we therefore assessed the long-term
outcomes at or beyond 12 months in this meta-analysis.
METHODS PubMed, EBSCO and Ovid databases were searched to
identify randomized controlled trials (RCT) comparing drug-eluting
balloons with balloon angioplasty for the management of femo-
ropopliteal and or infrapopliteal vascular disease. Outcomes of
target lesion revascularization (TVR), patency rates, death and
amputations were compared between the two groups using random
effects models and risk ratio (RR) with 95% conﬁdence intervals
were calculated.
RESULTS A total of 9 RCT’s were identiﬁed and included 1058
patients. Of these, 585 and 473 patients were randomized to DEB
and BA groups, respectively. The risk of TLR was signiﬁcantly lower
in the DEB group at 12 months (RR 0.34, 95% CI 0.22 – 0.53,
p<0.01) and 24 months (RR 0.37, 95% CI 0.16 – 0.84, p¼0.02)
compared to BA group. The patency rates were higher with the use
of DEB (RR 1.64, 95% CI 1.44 – 1.86, p<0.01). The risk of death was
similar in both the groups (RR 1.23, 95% CI 0.65 – 2.34, p¼0.52).
There was a favorable trend towards decrease in amputations with
the use of DEB, however this ﬁnding was not statistically signiﬁcant
(RR 0.64, 95% CI 0.17 – 2.53, p¼0.54). Heterogeneity was very low
among the included studies as assessed by Cochrane Q statistic
(I2¼25%). Publication bias was assessed by means of funnel plot
and this was deemed to be minimal.
B62 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5CONCLUSIONS Angioplasty of femoropopliteal and infrapopliteal
vascular stenosis with DEB is associated with signiﬁcantly lower risk
of TLR at both 12 and 24 months. DEB use is also associated with 64%
higher patency rates compared to BA. Further studies are necessary
assess the beneﬁts of mortality with the use of DEB for peripheral
vascular interventions.
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BACKGROUND Implantation of a transcatheter valve into a degen-
erated surgical bioprosthesis during aortic valve-in-valve (ViV) pro-
cedure may signiﬁcantly reduce the effective oriﬁce area (EOA)
available for blood ﬂow. We sought to investigate the impact of
prosthesis-patient mismatch (PPM) on hemodynamics and survival in
these patients.
METHODS A total of 657 data sets of aortic ViV procedures from the
Valve-in-Valve International Data Registry were investigated for the
current analysis. Severe PPM after ViV procedure was deﬁned as an
indexed EOA < 0.65cm2/m2 patient body surface area (BSA).
RESULTS Severe PPM was present in 202 patients after aortic ViV
implantation (30.7% total, 61.4% men, STS score 10.6%). Theincidence of severe PPM was higher in patients who received a
balloon-expandable device than a self-expandable device (38.4% vs.
21.5%, p<0.0001). Patients with severe PPM were younger (77.2  9.4
years vs. 78.7  8.1, p ¼ 0.05) and had larger body weight (80.9  18.9
kg vs. 72.6  14.1, p<0.0001) than those without severe PPM. In
addition, patients with severe PPM had higher aortic mean gradient
after the procedure (21.6  10 mmHg vs. 14.1  7.4) and lower aortic
valve area (1.03  0.2 cm2 vs. 1.66  0.44), in comparison with pa-
tients without severe PPM. Multivariate analysis revealed indepen-
dent predictors for having severe PPM after aortic ViV: effective
oriﬁce area before the procedure (Odds Ratio, OR 0.53 per 1cm2,
conﬁdence interval, CI, 0.3-0.94, p¼0.03), patient age (OR, 0.97 per
1year increment, CI, 0.94-0.99, p¼0.01), using a balloon expandable
device (OR, 2.82, CI, 1.78-4.46, p<0.001). In patients who survived
aortic ViV implantation procedure, one-year survival was not affected
by having severe PPM (93.3% vs. 93.8% in patients without severe
PPM, log rank p¼0.9).
CONCLUSIONS Severe PPM is common after aortic ViV implantation,
occurring in approximately one-third of patients. Predictors for severe
PPM include young age, stenotic surgical valves and balloon-
expandable device implantation. Despite higher valve gradients in
patients with severe PPM, one-year survival was similar to those
without severe PPM. Therefore, the risk of severe PPM should not
discourage operators from performing ViV procedures in inoperable
elderly patients.
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BACKGROUND Cardiac troponin-I (cTnI) is a marker of myocardial
injury and improvements in assay sensitivity allow precise quantiﬁ-
cation at extremely low serum concentrations. Increased cTnI con-
centrations are known to predict outcomes in patients with stable
coronary artery disease, although the underlying mechanisms remain
unknown. As rupture of thin-cap ﬁbroatheroma (TCFA) is thought
responsible for the majority of myocardial infarctions, we tested the
association between baseline cTnI concentration and plaque
classiﬁcation.
METHODS Patients undergoing planned percutaneous coronary
intervention (PCI) for stable angina pectoris (n¼99) underwent 3-
vessel virtual-histology intravascular ultrasound imaging (VH-IVUS,
Eagle-Eye Gold, Volcano Corp) before intervention. Virtual-histology
(VH)-TCFA were deﬁned as plaques (plaque burden >40%) with >10%
necrotic core in contact with lumen for 3 consecutive frames. High-
sensitivity cTnI was taken before PCI (ARCHITECT STAT high-sensi-
tivity cTnI assay, Abbott Laboratories, Abbott Park, Il, USA), with
patients subsequently stratiﬁed into tertiles. Major adverse cardio-
vascular events (MACE) were determined at follow-up (median 1,115
days).
RESULTS Serum cTnI concentrations for each tertile were; low 2.0
[2.0-3.0]ng/L, intermediate 4.0 [4.0-5.0]ng/L and high 7.0 [6.0-18.0]
ng/L. In comparison with the lowest cTnI tertile, highest tertile pa-
tients were older (679.7 vs. 59.810.6yrs, p¼0.002). However, there
were no other differences in demographics between these groups,
including diabetes mellitus (14.8 vs. 12.0%, p¼0.98), hypertension
(55.6 vs. 44.0%, p¼0.33) and serum creatinine (1.000.15 vs.
0.970.21mg/dL, p¼0.37). On 3-vessel VH-IVUS, total plaque number
(p¼0.27), plaque volume (p¼0.09), % necrotic core (p¼0.17) and %
calciﬁcation (p¼0.21) were similar between lowest and highest ter-
tiles. However, patients in the highest cTnI tertile had a higher
number of VH-TCFA, when compared with lowest tertile (2.0 [1.0-2.8]
vs. 1.0 [0.0-1.3], p¼0.027). On multivariable linear regression analysis,
cTnI concentration (p¼0.01) was independently associated with
